Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 4, 2002, Pages 257-265

  Lewis, Nancy L ^a   Scher, Richard ^a   Gallo, James M ^a   Engstrom, Paul F ^a   Szarka, Christine E ^a   Litwin, Samuel ^a   Adams, Andrea L ^a   Kilpatrick, Deborah ^a   Brady, Diane ^a   Weiner, Louis M ^a   Meropol, Neal J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Irinotecan; Phase I clinical trial; Raltitrexed

Indexed keywords

FLUOROURACIL; IRINOTECAN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUINAZOLINES; THIOPHENES;

EID: 0036389885     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0500-0     Document Type: Article

References (52)

1. Abigerges D, Armand JP, Chabot GG, de Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl Cancer Inst 86:464-469
2. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221
3. Armand JP (1996) CPT-11: clinical experience in phase I studies. Semin Oncol 23 [Suppl 3]:27-33
4. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR (1998) Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 4:1323-1330
5. Bissery MC, Mathieu-Boue A, Lavelle F (1991) Preclinical evaluation of CPT-11: a camptothecin derivative. Proc Am Assoc Cancer Res 32:402
6. Cao S, Rustum YM (2000) Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60:3717-3721
7. Cao S, Hapke G, Rustum YM (2000) Enhanced antitumor activity of Xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts. Proc Am Assoc Cancer Res 42:86
8. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245-259
9. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey G, Judson IR (1996) Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14:1495-1503
10. Clarke SJ, Beale PJ, Rivory LP (2000) Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 5:429-443
11. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM, on behalf of the Tomudex Colorectal Cancer Study Group (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16:2943-2952
12. Colucci G, Giuliani F, Giotta F, Galetta D, Brandi M, Nagliere E, Vinciarelli G, Maiello E (2001) Irinotecan (CPT-11) and raltitrexed (Tomudex) combination therapy in the treatment of advanced colorectal cancer (ACC): a phase I/II study. Proc ASCO 20:580
13. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K, 'Tomudex' Colorectal Cancer Study Group. (1995) 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate effecacy and reduced mucositis and leucopenia. Eur J Cancer 31A:1945-1954
14. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354
15. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047
16. Drewinko B, Freireich EJ, Gottlieb JA (1974) Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34:747-750
17. Escudero P, Espinosa J, Milla A, Salud A, Pericay C, Chacon I, Sanz M, Murias A, Dorta J, Bovio H, Baron MG (2001) An ongoing phase II study of raltitrexed (Tomudex) plus irinotecan in advanced colorectal cancer. Proc ASCO 20:120b
18. Ford HER, Cunningham D, Ross PJ, Rao S, Aherne GW, Benepal TS, Price T, Massey A, Vernillet L, Gruia G (2000) Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Br J Cancer 83:146-152
19. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 21:1033-1038
20. Gallo RC, Whang-Peng J, Adamson RH (1971) Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46:789-795
21. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
22. Grem JL, Sorensen JM, Cullen E, Takimoto CH, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ (1999) A phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Clin Cancer Res 5:2381-2391
23. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725
24. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes L (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51:5579-5586
25. Jackman AL, Gibson W, Brown M, Kimbell R, Boyle FT (1993) The role of reduced folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol 339:265-276
26. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50:5919-5924
27. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative, CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191
28. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5974
29. Ledermann JA, Leonard P, Seymour M (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345:145-146
30. Li LH, Fraser TJ, Olin EJ, Bhyuan BK (1972) Action of camptothecin on mammalian cells in culture. Cancer Res 32:2643-2650
31. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229
32. Matsui SI, Endo W, Wrzosek C, Haridas K, Seethatamulu P, Hausheer FH, Rustum YM (1999) Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD 1694, and a novel lipophilic topoisomerase I inhibitor, karenitecin, BNP1100: mechanisms and clinical implications. Eur J Cancer 35:984-993
33. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
34. Minderman H, Cao S, Yin MB, Matsui S, Slocum HK, Rustum YM (2000) Combining 5-FU with irinotecan in vivo: role of dose and schedule and cell cycle kinetic changes. Proc Am Assoc Cancer Res 41:212
35. Pazdur R, Vincent M (1997) Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicentre, North American trial. Proc ASCO 16:228a
36. Rivory LP, Robert J (1995) Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36:176-179
37. Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckhardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204
38. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135
39. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801-3807
40. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino)-1-piperidino) carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436
41. Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay MM, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16:2745-2751
42. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL, for the Irinotecan Study Group. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914
43. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345:144-146
44. Seitz JF, Cunningham D, Rath U, Olver IN, Van Cutsem E, Kerr D, Svensson C, Perez-Manga G, Harper P, Zalcberg J, Lowery K, Azab M, from the 'TOMUDEX' Study Group and Zeneca Pharmaceuticals (1996) Final results and survival data of a large randomised trial of 'Tomudex' in advanced colorectal cancer (ACC) confirm comparable eFcacy to 5-fluorouracil plus leucovorin (5-FU + LV). Proc ASCO 15:201
45. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, the CPT-11 Gastrointestinal Cancer Study Group (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913
46. Stevenson JP, Redlinger M, Kluiftmans L, Sun W, Algazy K, Giantonio B, Haller DG, Hardy C, Whitehead AS, O'Dwyer PJ (2001) Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol 19:4081-4087
47. Taguchi T, Wakui A, Hasegawa K, Niitani H, Furue H, Ohta K, Hattori T (1990) Phase I clinical study of CPT-11. Jpn J Cancer Chemother 17:115-120
48. Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced breast cancer. Jpn J Cancer Chemother 21:1017-1024
49. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T (1991) Late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother 18:1681-1689
50. Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL (2000) Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 18:659-667
51. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74
52. Vincenzi B, Santini D, Avvisati G, Fossati C, Finolexxi E, Tonini G (2001) Raltitrexed induces statistically significant platelet increases in colorectal cancer patients. Proc ASCO 20:119b